DT07 Rec'd PCT/PTO 0 2 FEB 2005

Form PT (REV 5-9		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER B45314
TRANSMITTAL LETTER TO THE UNITED STATES U.S. APPLIC			U.S. APPLICATION NO. (If known, see 37 C.F.R. 1.5) Unkno 10/523114	
	NATIONAL AI EP2003/0	PPLICATION NO. 08567	INTERNATIONAL FILING DATE 31 July 2003	PRIORITY DATE CLAIMED 2 August 2002 (earliest date)
TITLE	OF INVENTIO	N		
Vacc	ine Comp	osition Compri	sing Transferrin Binding Prot	ein and HSF From Gram Negative
Bacte	eria			
	CANT(S) FOR			
				ENOEL, Christiane FERON, Karine
			ncent WEYNANTS	CONTROL OF THE CONTRO
	ant nerewith nformation:	submits to the Ui	aited States Designated/Elected Offi	ice (DO/EO/US) the following items and
1 [x	l This is a F	TIRST submission	of items concerning a filing under	35 U.S.C. 371.
2. []			-	ncerning a filing under 35 U.S.C. 371.
3. [x] This expre delay exar	ess request to begi	n national examination procedures	(35 U.S.C. 371(f)) at any time rather than nit set in 35 U.S.C. 371(b) and PCT
4. [x		Demand for Internationity date.	ational Preliminary Examination wa	as made by the 19th month from the earliest
5. [x	a. [] is b. [x] ha	transmitted herew s been transmitted	Application as filed (35 U.S.C. 371) ith (required only if not transmitted by the International Bureau. he application was filed in the Uniter	
6. []	A translati	on of the Internat	ional Application into English (35 U	J.S.C. 371(c)(2)).
7. []	a. [] areb. [] hac. [] ha	e transmitted here ve been transmitte ve not been made	with (required only if not transmitte ed by the International Bureau.	er PCT Article 19 (35 U.S.C. 371(c)(3)) d by the International Bureau). g such amendments has NOT expired.
8. []	A translati	on of the amendm	ents to the claims under PCT Articl	le 19 (35 U.S. C. 371(c)(3)).
9. []	An oath or	declaration of the	e inventor(s) (35 U.S.C. 371(c)(4)).	
10. []	A translati U.S.C. 371		to the International Preliminary Ex	amination Report under PCT Article 36 (35
Items 1	1. to 16. be	low concern othe	er document(s) or information inc	
11. [x]	An Inform	ation Disclosure S	Statement under 37 C.F.R. 1.97 and	1.98; and Form PTO-1449.
12. []	An assignrand 3.31 is		r recording. A separate cover sheet	in compliance with 37 C.F.R. 3.28
	(Add clai		dment. Preliminary Amendment for US of ENT preliminary amendment.	originating cases only)
		e specification.	· •	
	Power of a	-		
		ct on a separate sh		·
		orm PCT/ISA/210).	
19. []	Other item	s or information.		

US APPLICATION NO. (if known see 37 CFR 1.50) Unknown 10/523114 INTERNATIONAL APPLICATION NO. PCT/EP2003/008567				ATTORNEYS DOCKE B45314	ET NO.
20. [X] The fol	llowing fees are subm		CALCULATION	PTO USE ONLY	
Basic	National Fee (37 C.I	F.R. 1.492(a)(1)-(5)):			
🗷 a) Bas	ic Filing Fee		\$300.00		
🗷 b) Exa	mination Fee		\$200.00		
	rch Fee				
		TOTAL OF ABOV	E CALCULATIONS =	\$1,000.00	
	0.00 for furnishing the			\$0.00	
months from the	earliest claimed priori				····
Claims	Number Filed	Number Extra	Rate		
Total claims	71 - 20 =	51	51 x \$50.00	\$2550.00	
Independent	4 - 3 =	1	1 x \$200.00	\$200.00	
claims			+ \$360.00		· · · · · · · · · · · · · · · · · · ·
Multiple depende	ent claims (if applicable	\$0.00			
TOTAL OF ABOVE CALCULATIONS =				\$2,750.00	
National Stage Application size fee - for each additional 50 sheets that exceed 100				\$0.00	
sheets. No. of 50 addt'l sheets $\underline{0}$ x \$250.00 =					
SUBTOTAL =				\$3,750.00	
Processing fee of \$130.00 for furnishing the English translation later than				\$	
□ 20 □ 30 months from the earliest claimed priority date (37 CFR 1.492(f)) +					
TOTAL NATIONAL FEE =				\$3,750.00	
				Amount to be	\$
				refunded	
				charged	\$

a.		A check in the amount of \$	to cover the above fees is enclosed
----	--	-----------------------------	-------------------------------------

- b. Please charge my Deposit Account No. 19-2570 in the amount of \$3,750.00 to cover the above fees.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

GLAXOSMITHKLINE

Corporate Intellectual Property - UW2220

P.O. Box 1539

King of Prussia, PA 19406-0939

Phone (610) 270-6150

Facsimile (610) 270-5090

SYMATURE

Jason C. Fedon

NAME

48,138

REGISTRATION NO.

n:\jcf\apps\b-cases\b45315\nat'l transmittal.doc

10/523114 DT05 Rec'd PCT/PTO 0.2 FEB 2005

"EXPRESS MAIL CERTIFICATE"

"EXPRESS MAIL" MAILING LABEL NUMBER EV608166135US DATE OF DEPOSIT <u>2 February 2005</u>

I HEREBY CERTIFY THAT THIS PAPER OR FEE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE "EXPRESS MAIL POST OFFICE TO ADDRESSEE" SERVICE UNDER 37 CFR 1.10 ON THE DATE INDICATED ABOVE AND IS ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

NAME OF PERSON MAILING PAPER OR FEE

(TYPE OR PRINT) Loppie Myers
SIGNATURE Sonaie Mys

Attorney Docket No.: B45314

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Berthet et al. 2 February 2005

Int'l Serial No.: PCT/EP2003/008567 Group Art Unit No.: unknown

Int'l Filing Date: 31 July 2003 Examiner: unknown

For: Vaccine Composition Comprising Transferrin Binding Protein and HSF

From Gram Negative Bacteria

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 CFR §§ 1.821 THROUGH 1.825

Commissioner for Patents Mail Stop: Sequence P.O. Box 1450 Alexandria, Va 22313-1450

(X)	I hereby state that the contents of the paper and computer readable copies of
	the Sequence Listing, submitted in accordance with 37 CFR §1.821(c) and (e),
	respectively, are the same.

	does not include new matter.
`	I hereby state that the submission filed in accordance with 37 CFR 81 821 (b)

I hereby state that the submission filed in accordance with 37 CFR §1.821 (g)

()	I hereby state that the submission filed in accordance with 37 CFR §1.821 (h)
		does not include new matter or go beyond the disclosure in the international
		application as filed.

()	I hereby state that the amendments, made in accordance with 37 CFR §1.825
		(a), included in the substitute sheet(s) of the Sequence Listing are supported in
		the application, as filed, at pages I hereby state that the substitute
		sheet(s) of the Sequence Listing does (do) not include new matter.

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(b), is the same as the amended Sequence Listing.

International Serial No.: PCT/EP2003/008567
International Filing Date: 31 July 2003

() I hereby state that the substitute copy of the computer readable form, submitted in accordance with 37 CFR §1.825(d), is identical to that originally filed.

Respectfully submitted,

Jason C. Fedon
Agent for Applicants
Registration No. 48,138

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-6150
Facsimile (610) 270-5090
N:UCF\apps\B-Cases\B45314\Sequence Listing Transmittal.doc